2025-04-19 - Analysis Report
## Eli Lilly and Co (LLY) Stock Performance Review

**0. Executive Summary:**

Eli Lilly and Co (LLY), a leading pharmaceutical company, has significantly outperformed the S&P 500 (VOO) over the analyzed period.  While showing strong growth, recent price action indicates potential consolidation or minor correction.  Fundamental analysis suggests robust profitability and financial health.


**1. Performance Comparison:**

Eli Lilly and Co. is a major pharmaceutical company known for its diverse portfolio of prescription drugs and innovative research.

* **Cumulative Return (LLY):** 312.35%
* **Cumulative Return (VOO):** 76.18%
* **Return Difference:** 236.2%
* **Relative Divergence:** 72.0% (This indicates LLY's performance is significantly higher than VOO, positioned at the 72nd percentile of its historical relative performance against VOO).


The table below shows the Compound Annual Growth Rate (CAGR), Maximum Drawdown (MDD), Alpha, Beta, and Market Capitalization (Cap) over various periods.  LLY demonstrates consistently high CAGR, but also shows increasing MDD, indicating higher volatility in later years.  Positive alpha suggests outperformance relative to the market. Beta, significantly greater than 1, shows higher volatility than the market.

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 14.0% | 55.9% | -19.0% | 0.1 | 67.7 |
| 2016-2018  | 42.0% | 58.6% | 21.0% | 0.1 | 95.1 |
| 2017-2019  | 55.0% | 58.6% | 21.0% | 1.4 | 110.4 |
| 2018-2020  | 57.0% | 58.6% | 27.0% | 0.7 | 144.7 |
| 2019-2021  | 116.0% | 60.5% | 55.0% | 0.4 | 240.3 |
| 2020-2022  | 111.0% | 64.9% | 102.0% | 0.3 | 322.6 |
| 2021-2023  | 152.0% | 64.9% | 132.0% | 0.3 | 519.2 |
| 2022-2024  | 171.0% | 72.1% | 150.0% | 0.3 | 692.0 |
| 2023-2025  | 144.0% | 76.8% | 130.0% | 0.2 | 754.3 |


**2. Recent Price Movement:**

* **Closing Price:** $839.96
* **5-Day Moving Average:** $763.76
* **20-Day Moving Average:** $787.29
* **60-Day Moving Average:** $830.71

The price is above all three moving averages, suggesting a potential upward trend. However, the recent sharp increase (14.3% change from the previous close) might indicate a short-term overbought condition and a possible correction.

**3. Technical Indicators:**

* **Market Risk Indicator (MRI):** 0.4244 (Medium Risk)
* **RSI:** 52.44 (Slightly above neutral; not overbought)
* **PPO:** 0.5654 (Positive, suggesting bullish momentum)
* **20-Day Relative Divergence Change:** +4.2% (Short-term upward momentum)
* **Expected Return (vs. S&P 500):** 77.8% over the long term (2+ years).  This is a substantial outperformance projection. The significant price increase from the previous close supports this expectation, although it also raises concerns about short-term volatility.


**4. Recent Earnings Analysis:**

| Date       | EPS    | Revenue       |
|------------|--------|----------------|
| 2024-10-30 | $1.08  | $11.44B        |
| 2024-08-08 | $3.29  | $11.30B        |
| 2024-04-30 | $2.49  | $8.77B         |
| 2023-11-02 | -$0.06 | $9.50B         |
| 2024-10-30 | -$0.06 | $9.50B         | *(Duplicate entry, likely an error)*


Earnings show significant variability.  The October 30th data appears duplicated, indicating a potential data entry error.  Further investigation into the data source is needed for accurate analysis.  However, overall revenue remains strong.


**5. Financial Information:**

**Revenue and Profitability:**

| Quarter | Revenue   | Profit Margin |
|---------|-----------|---------------|
| 2024-12-31 | $13.53B  | 82.24%        |
| 2024-09-30 | $11.44B  | 81.02%        |
| 2024-06-30 | $11.30B  | 80.80%        |
| 2024-03-31 | $8.77B   | 80.91%        |
| 2023-12-31 | $9.35B   | 80.88%        |

**Capital and Profitability:**

| Quarter | Equity    | ROE         |
|---------|-----------|-------------|
| 2024-12-31 | $14.19B  | 31.07%      |
| 2024-09-30 | $14.24B  | 6.81%       |
| 2024-06-30 | $13.56B  | 21.88%      |
| 2024-03-31 | $12.81B  | 17.51%      |
| 2023-12-31 | $10.77B  | 20.33%      |

Both revenue and profitability metrics are consistently high, indicating strong financial health.  ROE fluctuates, but remains generally positive.


**6. Overall Conclusion:**

LLY has demonstrated exceptional performance, significantly outperforming the S&P 500.  The strong financial fundamentals and positive technical indicators support a bullish outlook, especially for long-term investors.  However, the recent price surge and relatively high beta suggest increased volatility and a potential for short-term corrections.  Careful risk management is advised, and further investigation into the inconsistent earnings data is necessary for a complete picture. The high expected return compared to the S&P 500 warrants further investigation into the source and justification of the prediction.  The projection of a 77.8% excess return needs to be critically assessed to see what specific factors are driving this high growth expectation.
